SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/257189"
 

Search: onr:"swepub:oai:gup.ub.gu.se/257189" > An approach to supp...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer

Xue, Y. H. (author)
Martelotto, L. (author)
Baslan, T. (author)
show more...
Vides, A. (author)
Solomon, M. (author)
Mai, T. T. (author)
Chaudhary, N. (author)
Riely, G. J. (author)
Li, B. T. (author)
Scott, K. (author)
Cechhi, F. (author)
Stierner, Ulrika, 1952 (author)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Chadalavada, K. (author)
de Stanchina, E. (author)
Schwartz, S. (author)
Hembrough, T. (author)
Nanjangud, G. (author)
Nilsson, Jonas A, 1971 (author)
Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
Lowe, S. W. (author)
Reis, J. (author)
Rosen, N. (author)
Lito, P. (author)
show less...
 (creator_code:org_t)
2017-07-17
2017
English.
In: Nat Med. - : Springer Science and Business Media LLC. - 1078-8956. ; 23:8
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • The principles that govern the evolution of tumors exposed to targeted therapy are poorly understood. Here we modeled the selection and propagation of an amplification in the BRAF oncogene (BRAF(amp)) in patient-derived tumor xenografts (PDXs) that were treated with a direct inhibitor of the kinase ERK, either alone or in combination with other ERK signaling inhibitors. Single-cell sequencing and multiplex fluorescence in situ hybridization analyses mapped the emergence of extra-chromosomal amplification in parallel evolutionary trajectories that arose in the same tumor shortly after treatment. The evolutionary selection of BRAF(amp) was determined by the fitness threshold, the barrier that subclonal populations need to overcome to regain fitness in the presence of therapy. This differed for inhibitors of ERK signaling, suggesting that sequential monotherapy is ineffective and selects for a progressively higher BRAF copy number. Concurrent targeting of the RAF, MEK and ERK kinases, however, imposed a sufficiently high fitness threshold to prevent the propagation of subclones with high-level BRAF(amp). When administered on an intermittent schedule, this treatment inhibited tumor growth in 11/11 PDXs of lung cancer or melanoma without apparent toxicity in mice. Thus, gene amplification can be acquired and expanded through parallel evolution, enabling tumors to adapt while maintaining their intratumoral heterogeneity. Treatments that impose the highest fitness threshold will likely prevent the evolution of resistance-causing alterations and, thus, merit testing in patients.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

cell lung-cancer
braf-mutant
mek inhibition
raf inhibitors
phase-2
trial
open-label
melanoma
feedback
multicenter
vemurafenib
Biochemistry & Molecular Biology
Cell Biology
Research & Experimental
Medicine

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Nat Med (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view